ReviewFrontiers in physiology2026
Therapeutic targeting of local metabolic dysfunction in secondary lymphedema: mechanisms and opportunities.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary lymphedema is a chronic and progressive disorder resulting from impaired lymphatic drainage after surgery, radiotherapy, infection, trauma, or other lymphatic insults. Its pathological features include chronic inflammation, adipose deposition, fibrosis, and structural and functional damage to lymphatic vessels. Previous studies have mainly explained disease progression from the perspectives of lymphatic injury and tissue remodeling, while local metabolic dysfunction and the associated immune alterations remain insufficiently defined. Recent evidence indicates that lymphedematous tissues exhibit disturbances in both energy metabolism and lipid metabolism. These metabolic changes can impair the survival, proliferation, and reparative capacity of lymphatic endothelial cells and may also promote inflammation, adipose deposition, and fibrosis by regulating immune-cell behavior and function. This review systematically summarizes recent advances in local metabolic dysregulation in lymphedema, discusses pharmacological strategies targeting metabolic pathways and their current translational limitations, and aims to provide a conceptual framework for future studies on immunometabolic mechanisms and therapeutic interventions in secondary lymphedema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.